CFB
JANX icon

Cullen/Frost Bankers’s Janux Therapeutics JANX Stock Holding History

Cullen/Frost Bankers’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-396
Closed -$9.15K – 1394
2025
Q2 		$9.15K Buy
396
+220
+125% +$5.8K ﹤0.01% 1040
2025
Q1 		$4.75K Buy
176
+19
+12% +$716 ﹤0.01% 1051
2024
Q4 		$8.41K Sell
157
-16
-9% -$846 ﹤0.01% 907
2024
Q3 		$7.86K Buy
173
+4
+2% +$174 ﹤0.01% 924
2024
Q2 		$7.08K Buy
+169
New +$7.93K ﹤0.01% 893

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cullen/Frost Bankers's JANX Position: Q3 2025 in Review

Cullen/Frost Bankers sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 396 shares — an estimated $9.15K sold.

Cullen/Frost Bankers first reported a position in JANX in Q2 2024 and held it in 5 quarters. The position peaked at $9.15K in Q2 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

  • Cullen/Frost Bankers reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cullen/Frost Bankers sold 396 Janux Therapeutics shares in Q3 2025, an estimated $9.15K.
  • Cullen/Frost Bankers first reported a position in Janux Therapeutics in Q2 2024 and held it in 5 quarters.
  • Cullen/Frost Bankers's Janux Therapeutics position peaked at $9.15K in Q2 2025.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Cullen/Frost Bankers's 13F filing for Q3 2025, filed 31 Oct 2025.